GSK (NYSE:GSK) & TherapeuticsMD (NASDAQ:TXMD) Head to Head Comparison

TherapeuticsMD (NASDAQ:TXMD) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability and institutional ownership.

Insider and Institutional Ownership

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares TherapeuticsMD and GSK”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02 million	7.70	-$570,000.00	$0.02	100.50
GSK	$43.07 billion	2.19	$7.54 billion	$3.20	14.54

GSK has higher revenue and earnings than TherapeuticsMD. GSK is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares TherapeuticsMD and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
GSK	14.56%	43.23%	11.60%

Volatility & Risk

TherapeuticsMD has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for TherapeuticsMD and GSK, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1	0	0	0	1.00
GSK	2	7	1	1	2.09

GSK has a consensus target price of $56.50, suggesting a potential upside of 21.39%. Given GSK’s stronger consensus rating and higher probable upside, analysts clearly believe GSK is more favorable than TherapeuticsMD.

Summary

GSK beats TherapeuticsMD on 11 of the 15 factors compared between the two stocks.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.